Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Amoxicillin/clavulanate emerges as best antibiotic for childhood bronchiectasis

Publish date:: October 18, 2019

Key clinical point: Relative to azithromycin for nonsevere bronchiectasis in children, amoxicillin/clavulanate was more effective.

Major finding: Relative to placebo, the risk ratio for exacerbation resolution was higher for amoxicillin/clavulanate (risk ratio, 1.5) than azithromycin (RR, 1.4)

Data Source: Double-blind, multicenter, placebo-controlled trial.

Disclosures: Dr. Goyal reported no potential conflicts of interest.

Citation:

Goyal V et al. Lancet Respir Med. 2019;7:791-801.

This Week's Must Reads

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Three genes could predict congenital Zika infection susceptibility,

‘Excellent short-term outcomes’ seen in HCV+ liver transplants to HCV– recipients,

Must Reads in Pediatrics

COVID-19–induced drop in first measles vaccinations sparks resurgence concerns,

Three genes could predict congenital Zika infection susceptibility,

Obesity, hypoxia predict severity in children with COVID-19,

Two consecutive negative FUBC results clear S. aureus bacteremia,

Chinese American families suffer discrimination related to COVID-19,